SER — Serina Therapeutics Inc
AMEX · Healthcare · Biotechnology
$2.50
+$0.08 (+3.31%)
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX. It is led by Steven A. Ledger, based in 601 Genome Way, Huntsville, AL, United States, 35806, with about 16 employees. Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Latest reported SER revenue for 2025-09-30 was $0. Net income was -$4.6M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. SER currently screens at market cap $29.7M.
Use this SER page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SER quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SER SEC filings page. Lician reads the product cache first so this HTML stays unique to Serina Therapeutics Inc even when a live quote feed is slow.
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
SER Key Statistics
Market Cap
$29.70M
Volume
15,981
Previous Close
$2.63
Day Range
$2.55 – $2.78
P/B Ratio
2.34
EPS
-$1.51
Revenue
$56.00K
Net Income
-$11.21M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-98.2%
Profit Margin
-20012.5%
Employees
16
SER Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $56.00K | $3.15M | $34.00K | $144.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.21M | $5.27M | -$10.52M | -$8.69M |
| EPS (Diluted) | -$1.51 | $0.73 | -$9.70 | $0.00 |
Total Assets
$6.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.67M
Operating Cash Flow
-$17.14M
Free Cash Flow
$0.00
Serina Therapeutics Inc Company Information
- CEO & Director
- Steven A. Ledger
- Headquarters
- 601 Genome Way, Huntsville, AL, United States, 35806
- Website
- serinatherapeutics.com
- Phone
- 256 327 9630
- IPO / Founded
- 2018-11-29
- Sector
- Healthcare
- Industry
- Biotechnology